1Ma X,Does M,Raza A,et al.Myelodysplastic syndromes:incidence and survival in the United States[J].Cancer,2007,109:1536.
2Jabbour E,Garcia-Manero G,Batty N,et al.Outcome of patients with mye lodysplastic syndrome after failure of decitabine therapy[J].Cancer,2010,116:3830.
3Garcia-Manero G,Fenaux P.Hypomethylating agents and other novel strategies in myelodysplastic syndromes[J].J Clin Oncol,2011,29:516.
4Jiri M,Christopher A,Jacques D,et al.Multivariate and subgroup analyses of a randomized,multinational,phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor or intermediate-risk cytogenetics[J].BMC,2014,14:69.
5Kantarjian H,Oki Y,Garcia-Manero G,et al.Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia[J].Blood,2007,109:52.
6Steensma DP,Beer MR,Slack JL,et al.Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes:the alternative dosing for patient treatment(ADOPT)trial[J].J Clin Oncol,2009,27:3842.
7Kantarjian HM,O'Brien S,Shan J,et al.Update of the deciabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome[J].Cancer,2007,109:265.
10Lyons RM.Myelodysplastic syndromes:therapy and outlook[J].AM J Med,2012,125(l):18.
二级参考文献19
1Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues [ M ]. Lyon, France : IARC, 2008.
2Vardiman JW, Thiele J, Arber DA. , et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes[ J]. Blood ,2009,114:937 - 951.
3Mufti GJ, Bennett JM, Goasguen J, et al. Diagnosis and classification of myelodysplastic syndrome : International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts[ J]. Haematologica ,2008,93 : 1712 - 1717.
6Tien H F,Tang J H,Tsay W,et al.Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation[].British Journal of Haematology.2001
7Momparler R L,Bovenzi V.DNA methylation and cancer[].Journal of Cellular Physiology.2000
8Daskalakis M,Nguyen TT,Nguyen C,et al.Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2-deoxycytidine (decitabine) treatment[].Blood.2002
9V Zagonel,Re G Lo,G Marotta.5-Aza-2-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes[].Leukemia.1993
10de PADUA SILVA L,de LIMA M,KANTARJIAN H,et al.Feasibility of allo-SCT after hypomethylating therapy withdecitabine for myelodysplastic syndrome[].Bone Marrow Tra-nsplant.2009
